

FREESTYLE LIBRE SENSOR:

- ♦ for self-monitoring of blood glucose in diabetic persons age 4 years or over.

Upon the initiation of treatment, the person:

- under age 18 years must be suffering from type 1 diabetes;
- age 18 years and over must be treated with intensive insulin therapy (treatment by insulin pump or ≥ 3 insulin injections per day) and must meet one or more of the following criteria:
 - non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient, despite optimal management of the disease;
 - frequent episodes of hypoglycemia in the last year, despite compliance with a glycemia management plan;
 - inability to recognize or signal hypoglycemia symptoms.

The initial request is authorized for a period of six months to assess the ability of patients to use FreeStyle Libre™ and wear the sensor.

The request for continuation of treatment is authorized if the person shows optimal use of FreeStyle Libre™, i.e., at least 70% of the time.

An annual clinical reassessment by the prescriber is recommended to ensure that the person is using the sensor at least 70% of the time.

FREMANEZUMAB:

- ♦ for prophylactic treatment of migraines in persons with at least four days of migraines per month and a diagnosis established according to the criteria of the International Headache Society:
 - in the case of an intolerance or a contraindication to at least three appropriate prophylactic drugs, including at least one tricyclic antidepressant, one anticonvulsant and one antihypertensive drug, or if these are ineffective.

In the initial request, the prescriber must provide the number of days of migraine per month.

The maximum duration of the initial authorization is six months.